Sovargen Dosed First Patient in Paxalisib Clinical Trial
The milestone in a study for rare neurological disorders triggered a $2 million payment to partner Kazia Therapeutics.
Updated on Sept. 22, 2026 in Biotech
Live Poll
Do you believe the medical industry is prioritizing the development of treatments for rare diseases enough?
Sovargen Co. has administered the first dose of paxalisib to a patient in a Phase 1b/2a clinical trial. The study evaluates the drug as a potential treatment for focal cortical dysplasia type 2 and tuberous sclerosis complex.
Why it matters
The trial targets rare neurological disorders where somatic mutations in the PI3K/Akt/mTOR pathway drive treatment-resistant seizures. Because no approved therapies currently exist for focal cortical dysplasia type 2, this research represents a significant potential shift in care.
Paxalisib is an oral, brain-penetrant dual inhibitor of PI3K and mTOR. The trial is designed to test the efficacy of the drug in adult patients suffering from specific mTORopathy-related epilepsies.
The players
Sovargen Co.
This Korean biotech company focuses on the development and commercialization of treatments for mTORopathy-related epilepsies.
Kazia Therapeutics
Headquartered in Sydney, Australia, this company focuses on the development of novel oncology and neurology therapeutics.
The details
Sovargen Co. maintains the rights to develop, manufacture, and commercialize the drug for these conditions under an exclusive agreement. The ongoing trial is the first to evaluate the drug's performance in these specific rare neurological cohorts.
Timeline
March 2024: Kazia Therapeutics and Sovargen Co. entered an exclusive licensing agreement.
September 22, 2026: The first patient was officially dosed in the clinical trial.
The Big Picture
This clinical trial builds upon foundational research into the PI3K/Akt/mTOR signaling pathway. By targeting this mechanism, the study seeks to address a critical gap in treating patients whose seizures are resistant to standard medical interventions.
The development of brain-penetrant inhibitors could eventually provide new treatment options for patients with rare forms of epilepsy. Patients and families currently managing these conditions face significant limitations as no approved therapies exist for focal cortical dysplasia type 2.
The takeaway
This trial marks a notable move in the pursuit of specialized treatments for rare neurological disorders. Continued research will determine if this dual inhibitor can offer a breakthrough for patients suffering from treatment-resistant seizures.
Further reading
Learn more about the latest innovations in the Biotech sector.
Live Poll
Do you believe the medical industry is prioritizing the development of treatments for rare diseases enough?
